DE69219787D1 - Immuntherapeutische vektorkonstrukte gegen krebs - Google Patents

Immuntherapeutische vektorkonstrukte gegen krebs

Info

Publication number
DE69219787D1
DE69219787D1 DE69219787T DE69219787T DE69219787D1 DE 69219787 D1 DE69219787 D1 DE 69219787D1 DE 69219787 T DE69219787 T DE 69219787T DE 69219787 T DE69219787 T DE 69219787T DE 69219787 D1 DE69219787 D1 DE 69219787D1
Authority
DE
Germany
Prior art keywords
altered
altered cellular
expression
recombinant virus
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69219787T
Other languages
English (en)
Other versions
DE69219787T2 (de
Inventor
Sunil Chada
Mordechai Bodner
Douglas Jolly
Jack Barber
Cataline Dejesus-Harkleroad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Publication of DE69219787D1 publication Critical patent/DE69219787D1/de
Application granted granted Critical
Publication of DE69219787T2 publication Critical patent/DE69219787T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69219787T 1991-11-29 1992-11-30 Immuntherapeutische vektorkonstrukte gegen krebs Expired - Fee Related DE69219787T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80032891A 1991-11-29 1991-11-29
PCT/US1992/010309 WO1993010814A1 (en) 1991-11-29 1992-11-30 Anti-cancer immunotherapeutic vector constructs

Publications (2)

Publication Number Publication Date
DE69219787D1 true DE69219787D1 (de) 1997-06-19
DE69219787T2 DE69219787T2 (de) 1997-08-28

Family

ID=25178122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69219787T Expired - Fee Related DE69219787T2 (de) 1991-11-29 1992-11-30 Immuntherapeutische vektorkonstrukte gegen krebs

Country Status (10)

Country Link
US (1) US5693522A (de)
EP (1) EP0615453B1 (de)
JP (1) JPH07501942A (de)
AT (1) ATE152915T1 (de)
AU (1) AU671971B2 (de)
CA (1) CA2117303C (de)
DE (1) DE69219787T2 (de)
FI (1) FI942503A (de)
NO (1) NO941986L (de)
WO (1) WO1993010814A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
JPH08504095A (ja) * 1992-09-18 1996-05-07 カンジ，インコーポレイテッド 腫瘍抑制遺伝子を有するレトロウイルスベクターによる遺伝子療法
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
US5629192A (en) * 1994-02-04 1997-05-13 The United States Of America As Represented By The Department Of Health And Human Services ETS1 gene: a human tumor suppressor gene
CA2189032A1 (en) * 1994-04-29 1995-11-09 Ruth A. Gjerset Enhancing the sensitivity of tumor cells to therapies
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
CA2232344C (en) 1995-10-20 2005-04-05 University Of Nebraska Board Of Regents Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
US6365151B1 (en) * 1996-01-19 2002-04-02 Philadelphia Health And Educational Corporation Cellular immunogens comprising cognate proto-oxogenes
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (de) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
PT991403E (pt) * 1997-01-30 2003-08-29 Chiron Corp Uso de microparticulas com antigenio adsorvido para estimular respostas imunes
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU7486898A (en) 1997-05-13 1998-12-08 Stuart D Edwards Global medical treatment method and apparatus
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
DE69942100D1 (de) 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
GB9907414D0 (en) 1999-03-31 1999-05-26 Cancer Res Campaign Tech Improvements relating to prodrugs
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6399743B1 (en) 1999-05-14 2002-06-04 Dept. Of Veterans Affairs Isolation and characterization of a rat epidermal growth factor related protein
US7049410B2 (en) * 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
AU6944100A (en) * 1999-09-01 2001-03-26 Johns Hopkins University, The Beta-catenin, tcf-4, and apc interact to prevent cancer
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US6432409B1 (en) 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
AU2002226030A1 (en) 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1399183B1 (de) 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimere alphavirus-replikon-partikel
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
CA2499123A1 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-key/antigenic epitope hybrid peptide vaccines
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2007047749A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2646891A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2010537B1 (de) * 2006-03-23 2011-12-28 Novartis AG Imidazochinoxalinverbindungen als immunmodulatoren
WO2007109810A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Methods for the preparation of imidazole-containing compounds
AU2009209518A1 (en) * 2008-01-28 2009-08-06 Milux Holding S.A. A drainage device comprising an active filter
EP2391748A4 (de) * 2009-01-28 2012-08-01 Antigen Express Inc Li-key-hybridpeptide zur modulation der immunreaktion auf influenza
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
BR112018013967A2 (pt) 2016-01-19 2019-02-05 Pfizer vacinas contra o câncer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) * 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4965196A (en) * 1983-01-19 1990-10-23 Genentech, Inc. Polycistronic expression vector construction
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4931275A (en) * 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
DE3854313D1 (de) * 1987-05-29 1995-09-21 Dana Farber Cancer Inst Inc Cis-Wirkung-Repressionen-Sequenzen, Cis-Wirkung-Antirepressionen-Sequenzen, Vektoren, Verfahren zur Vorbereitung und Anwendung.
WO1989001973A2 (en) * 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
ATE117375T1 (de) * 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
WO1989005349A1 (en) * 1987-12-09 1989-06-15 The Australian National University Method of combating viral infections
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
EP0465529B1 (de) * 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech Inc Her2 extrazellulare domäne
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
NO941986L (no) 1994-07-27
CA2117303A1 (en) 1993-06-10
AU3229793A (en) 1993-06-28
AU671971B2 (en) 1996-09-19
FI942503A0 (fi) 1994-05-27
WO1993010814A1 (en) 1993-06-10
CA2117303C (en) 2000-10-17
EP0615453A1 (de) 1994-09-21
ATE152915T1 (de) 1997-05-15
JPH07501942A (ja) 1995-03-02
DE69219787T2 (de) 1997-08-28
NO941986D0 (no) 1994-05-27
EP0615453B1 (de) 1997-05-14
FI942503A (fi) 1994-05-27
US5693522A (en) 1997-12-02

Similar Documents

Publication Publication Date Title
DE69219787T2 (de) Immuntherapeutische vektorkonstrukte gegen krebs
DE68928884T2 (de) Rekombinante Retroviren
CA2066053A1 (en) Recombinant retroviruses delivering vector constructs to target cells
CY1113689T1 (el) Εξασθενημενοι ιοι αρνητικου κλωνου με αλλοιωμενη δραστικοτητα ανταγωνισμου ιντερφερονης για χρηση ως εμβολια και φαρμακευτικα προϊοντα
DE69937294D1 (de) Von cyclophilin b abstammende tumorantigen-peptide
DE59410380D1 (de) Endosomolytisch wirksame partikel
RU95112465A (ru) Пирановые соединения, фармацевтическая композиция, способ получения и промежуточные соединения
NO885213L (no) Stabiliserte legemidler, fremgangsmaate til deres fremstilling samt stabile legemiddeltilberedninger.
DK368786A (da) Fremgangsmaade til fremstilling af erythropoietin
ATE83374T1 (de) Neue galenische form von fenofibrat.
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
DK11789D0 (da) Rekombinante vaccinia-vira
DK0588578T3 (da) Immunogener
KR860005636A (ko) 활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
NO974693L (no) Farmasöytisk preparat inneholdende N-klorfenylkarbamater, N-klorfenyltiokarbamater og N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus i pattedyr
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
DE69322872D1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
RU94028669A (ru) Векторная конструкция, рекомбинантные вирусы, рекомбинантный ретровирус, клетки-мишени, композиция, применение композиции
DK0382075T3 (da) Phenylhydrazoner af beta-jononer, fremstilling heraf og heraf fremstillede lægemidler og kosmetika

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8328 Change in the person/name/address of the agent

Free format text: DERZEIT KEIN VERTRETER BESTELLT

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee